IP Library › Granted Patent US 11,541,102
Granted Patent B2
US 11,541,102 · App. 16/779,913 · Granted Jan 3, 2023

Methods for inducing cell division of postmitotic cells

Inventors: Tamer M. A. Mohamed (San Francisco, CA); Deepak Srivastava (San Francisco, CA)
Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
A61K38/1709A61K35/30A61K35/34A61K35/36A61K35/39A61K38/45A61P9/10C12N5/06C12Y207/11022A61K35/00A61K2300/00C12N2310/111
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,541,102
App. No.
16/779,913
Granted
Jan 3, 2023
Kind
B2
Abstract

The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

Claims (16)

1. A method of treating myocardial infarction (MI) in a subject in need thereof, comprising administering to the subject effective amounts of

a) cyclin-dependent kinase-1 (CDK1);

b) cyclin B1 (CCNB1);

c) a cyclin-dependent kinase-4 (CDK4); and

d) a cyclin D1 (CCND1).

2. The method of claim 1 , comprising administering a viral vector comprising a polynucleotide encoding the CDK1, the CCNB1, the CDK4, and the CCND1.

3. The method of claim 1 , comprising administering two viral vectors comprising polynucleotides encoding the CDK1, the CCNB1, the CDK4, and the CCND1.

4. The method of claim 1 , comprising administering an effective amount of a TGF-β inhibitor.

5. The method of claim 4 , wherein the TGF-β inhibitor is SB431542.

6. The method of claim 4 , wherein the TGF-β inhibitor is dexamethasone.

7. The method of claim 1 , wherein the method promotes cardiac cell proliferation.

8. The method of claim 7 , wherein cardiac cell proliferation is assayed by increase in phosphor-histone H3 (PHH3) staining of cTnT+ cells.

9. The method of claim 7 , wherein cardiac cell proliferation is assayed by increase in 5-ethynyl-2′-deoxyuridine (EdU) staining of cTnT+ cells.

10. The method of claim 1 , wherein the method decreases scar size after MI.

11. The method of claim 1 , wherein the method decreases decrease in ejection fraction (EF).

12. A viral vector, comprising a polynucleotide encoding cyclin-dependent kinase-1 (CDK1); cyclin B1 (CCNB1); a cyclin-dependent kinase-4 (CDK4); and a cyclin D1 (CCND1).

Continuity (4)
Continuation 15564752
Provisional Application 62151321 · Apr 22, 2015
Provisional Application 62144244 · Apr 7, 2015
Related Publication 20200165691A1 · May 28, 2020
Cited By (1)
US 12,661,384